

Multiple Myeloma

**A Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma**

**Trial Status**  
Recruiting

**Trial Runs In**  
7 Countries

**Trial Identifier**  
NCT05646836  
2022-001204-18,2023-505212-38-00  
GO43980

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT05646836 2022-001204-18,2023-505212-38-00 GO43980**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---